MRI for Predicting Radiation Changes in Oral Cavity or Skull Base Tumors

This study is looking at how well serial Magnetic Resonance Imaging (MRI) can predict changes in normal tissues after radiation therapy for people with oral cavity or skull base tumors. You would receive a contrast agent (a special dye given through an IV) and undergo multiple MRI scans. Researchers hope to see if these MRIs can help predict osteoradionecrosis (bone damage caused by radiation) and other radiation-induced effects. To join, you must be over 18, have a good performance status (ECOG score 0-2, meaning you are fully active or can carry out light work), and have a histologically proven tumor of the oral cavity, oropharynx, or skull base. The study aims to understand the relationship between MRI findings and future radiation effects. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 425 participants, divided into two groups (cohorts).
What's involved
You would receive a contrast agent intravenously and undergo MRI scans at several time points, including before, during, and after radiation therapy or surgery, over a period of up to 3 years.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for up to 3 years after completing radiation therapy or surgery, with primary endpoints measured up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04265430

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

Recruiting
PHASE4Ages 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~425 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Contrast AgentMagnetic Resonance ImagingQuality-of-Life AssessmentQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Radiotherapy-attributable imaging for normal tissue injury
Measured over Up to 1 year
+2 more outcomes measured
Malignant Oral Cavity Neoplasm
Malignant Skull Base Neoplasm
Osteoradionecrosis
1 sites across 1 states
Texas1
  • Stephen Y Lai · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients older than 18 years of age
Patients with good performance status (ECOG score 0-2)
Patients willing to give written informed consent.
Patients with histologically proven malignant neoplasms of the oral cavity, oropharynx or skull base.
Patients currently dispositioned to treatment with radiotherapy and/or antiresorptive or antiangiogenic medication therapy
Patients with a clinical diagnosis of ORN or MRONJ following treatment for cancer
Patients previously dispositioned to treatment with radiotherapy and/or antiresorptive or antiangiogenic medication therapy

Exclusion

Patients unable to tolerate DW-MRI or DCE-MRI or having an estimated GFR \< 30ml/min/1.73m2.
Patients with contraindication to MRI (e.g. non-MRI compatible metallic implants)
  • Radiotherapy-attributable imaging for normal tissue injuryUp to 1 year

    Will correlate whether post-therapy alterations in the observed multi-parametric imaging features can be used as surrogate bio-markers of normal tissue injury

  • Dose-response correlation between imaging biomarkersUp to 1 year

    Penalized spline mixed regression will be used to characterize the induced functional relationships between the delivered dose and imaging biomarkers identified at each imaging time point. Doses for which 95% confidence interval estimates of mean trajectory fail to overlap will characterize ranges that yield significantly different levels of dose-dependent modulation.

  • Dose-response correlation between subsequent radiation-induced effectsUp to 1 year

    Penalized spline mixed regression will be used to characterize the induced functional relationships between the delivered dose and imaging biomarkers identified at each imaging time point. Doses for which 95% confidence interval estimates of mean trajectory fail to overlap will characterize ranges that yield significantly different levels of dosedependent modulation